Feasibility and Effects of a Realistic Stressful Virtual Environment on Balance and Mobility in Healthy Adults: A Pilot Study
Does a Real-life Stressful Virtual Environment Change Balance and Mobility Performance? A Pilot Feasibility Study
The goal of this pilot clinical trial is to evaluate the feasibility of a new approach to assessing balance and mobility in everyday situations by performing established clinical tests in a stressful virtual reality environment. The study involves healthy adults aged 18 years and older with no self-reported neurological disorders or history of epilepsy.
The main questions it aims to answer are:
- Is it feasible to perform standard balance and mobility tests in a virtual reality environment simulating a busy train station?
- How does this virtual environment affect participants' balance and mobility test performance?
- How do participants experience the virtual environment, including their sense of being there and any discomfort or virtual reality sickness?
Researchers will compare each participant's performance with and without virtual reality to see if the virtual environment changes balance and mobility test results.
Participants will:
- Spend a brief familiarisation period in the virtual environment before testing.
- Complete the Mini-BESTest, which assesses balance through a series of tasks, with and without virtual reality.
- Complete the Timed Up and Go test, which involves standing up from a chair, walking three meters, turning, returning, and sitting down, with and without virtual reality and with and without counting backwards by threes.
- Complete the 10-Meter Walk Test at comfortable and fast walking speeds, with and without virtual reality.
- Complete questionnaires after the final virtual reality exposure about their sense of being in the virtual environment and any symptoms of discomfort or sickness.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Brussels, Belgien
- VUB
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- healthy adults aged 18 years and older
Exclusion Criteria:
- self-reported neurological disorders
- history of epilepsy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Balance and mobility assessment with and without virtual reality
All participants complete the Mini-BESTest, Timed Up and Go test, and 10-Meter Walk Test both without a virtual reality headset and while wearing a headset displaying a busy virtual train station. The Timed Up and Go test is performed with and without an additional cognitive task in each condition. |
Participants wear a standalone virtual reality headset (Meta Quest 3) displaying a busy train-station environment while completing standard balance and mobility assessments. The environment includes moving pedestrians, animated displays, and recorded train-station sounds. Participants undergo a brief familiarisation period before testing. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of participants completing all planned assessments
Zeitfenster: At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.
|
Proportion of participants who complete all planned assessments in both non-virtual reality (noVR) and virtual reality (VR) conditions. The predefined feasibility criterion is completion by at least 80% of participants. |
At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.
|
|
Number of virtual reality-related technical issues
Zeitfenster: From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.
|
technical feasibility: assessed by the number and type of VR-related technical issues encountered |
From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.
|
|
Proportion of complete outcome measurements per test and condition
Zeitfenster: Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.
|
data completeness: quantified as the proportion of complete outcome data per test and condition (criterion: ≥80% complete data) |
Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.
|
|
Percentage increase in assessment time with virtual reality compared with no virtual reality
Zeitfenster: From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.
|
assessment burden: reflected by total assessment time, considered acceptable if VR assessments required no more than 20% additional time compared to noVR conditions |
From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.
|
|
Number of participants experiencing adverse events during assessment
Zeitfenster: From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.
|
Number of participants experiencing at least one adverse event during the assessment session, including both virtual reality and non-virtual reality conditions, or within 15 minutes after its completion. |
From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.
|
|
Virtual Reality Sickness Questionnaire scores (VRSQ)
Zeitfenster: single session, Immediately after completion of the virtual reality session on Day 1.
|
The VRSQ is a modified version of the Simulator Sickness Questionnaire and consists of nine items assessing symptoms of VR-induced discomfort. These items are grouped into two subdomains: oculomotor discomfort (items 1-4) and disorientation (items 5-9). Each item is rated on a four-point Likert scale ranging from 0 ("not at all") to 3 ("severe"). Subscale scores are normalized and combined to yield a total VRSQ score, with higher scores indicating greater VR sickness. |
single session, Immediately after completion of the virtual reality session on Day 1.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
iGroup Presence Questionnaire subscale scores
Zeitfenster: single session, Immediately after completion of the virtual reality session on Day 1.
|
The IPQ assesses different dimensions of presence and consists of items grouped into four subscales: General Presence (GP), Spatial Presence (SP), Involvement (INV), and Experienced Realism (ER). Items are rated on a seven-point Likert scale ranging from 0 to 6, with higher scores indicating a stronger sense of presence within the virtual environment. |
single session, Immediately after completion of the virtual reality session on Day 1.
|
|
Within-participant difference in Mini-BESTest total score between virtual reality and non-virtual reality conditions
Zeitfenster: single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
|
The Mini-Balance Evaluation Systems Test (Mini-BESTest) is a standardized clinical assessment of dynamic balance and a shortened version of the Balance Evaluation Systems Test (BESTest). It consists of 14 items covering four balance domains: anticipatory postural adjustments (items 1-3), reactive postural control (items 4-6), sensory orientation (items 7-9), and dynamic gait (items 10-14) (A.3). Each item is scored on a three-level ordinal scale (0-2), resulting in a maximum total score of 28 points, with higher scores indicating better balance performance. For items requiring bilateral assessment (items 3 and 6), the lower score was retained. |
single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
|
|
Within-participant difference in single-task and cognitive dual-task Timed Up and Go completion time between virtual reality and non-virtual reality conditions
Zeitfenster: single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.
|
Participants are instructed to stand up from a chair, walk three meters at a safe and comfortable speed, cross a marked line on the floor, turn around, walk back to the chair, and sit down. The time required to complete the task was recorded in seconds. In addition to the standard single-task TUG, a cognitive dual-task version was administered. During the dual-task TUG, participants were asked to count backwards by threes from a randomly selected number between 20 and 100 while performing the motor task. Both single-task and dual-task TUG were performed under noVR and VR conditions, resulting in four TUG conditions in total. |
single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.
|
|
Within-participant difference in comfortable walking speed between virtual reality and non-virtual reality conditions
Zeitfenster: single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1
|
The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions. For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second. |
single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1
|
|
Within-participant difference in fast walking speed between virtual reality and non-virtual reality conditions
Zeitfenster: single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
|
The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions. For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second. |
single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Bart Jansen, PhD, ETRO, Vrije Universiteit Brussel
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ECHW_W_021
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
De-identified individual participant data underlying the results reported in publications arising from this study will be made available by the corresponding author upon reasonable request following publication.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .